ALK and anaplastic large cell lymphoma: We profiled gene expression in pre-treatment biopsies from non-relapsing and relapsing patients with ALK+ ALCL to provide an additional indicator that could help to identify patients with a high risk of relapse and those of low risk who could benefit from a therapy reduction.